Zhang, Y., Liu, P., Cai, J., Jing, H., Zou, L., Huang, H., . . . Cai, Q. (2022). Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study. Wiley.
Chicago Style (17th ed.) CitationZhang, Yuchen, et al. Ibrutinib as Monotherapy Versus Combination Therapy in Chinese Patients with Relapsed/refractory Mantle Cell Lymphoma: A Multicenter Study. Wiley, 2022.
MLA (9th ed.) CitationZhang, Yuchen, et al. Ibrutinib as Monotherapy Versus Combination Therapy in Chinese Patients with Relapsed/refractory Mantle Cell Lymphoma: A Multicenter Study. Wiley, 2022.
Warning: These citations may not always be 100% accurate.